Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Non-phytoseiid Mesostigmata within citrus orchards in Florida: species distribution, relative and seasonal abundance within trees, associated vines and ground cover plants and additional collection records of mites in citrus orchards

Seven citrus orchards on reduced- to no-pesticide spray programs in central and south central Florida were sampled for non-phytoseiid mesostigmatid mites. Inner and outer canopy leaves, fruits, twigs and trunk scrapings were sampled monthly between August 1994 and January 1996. Open flowers were sampled in March from five of the sites. A total of 431 samples from one or more of 82 vine or ground cover plants were sampled monthly in five of the seven orchards. Two of the seven orchards (Mixon I and II) were on full herbicide programs and vines and ground cover plants were absent. A total of 2,655 mites (26 species) within the families: Ascidae, Blattisociidae, Laelapidae, Macrochelidae, Melicharidae, Pachylaelapidae and Parasitidae were identified. A total of 685 mites in the genus Asca (nine species: family Ascidae) were collected from within tree samples, 79 from vine or ground cover plants. Six species of Blattisociidae were collected: Aceodromus convolvuli, Blattisocius dentriticus, B. keegani, Cheiroseius sp. near jamaicensis, Lasioseius athiashenriotae and L. dentatus. A total of 485 Blattisociidae were collected from within tree samples compared with 167 from vine or ground cover plants. Low numbers of Laelapidae and Macrochelidae were collected from within tree samples. One Zygoseius furciger (Pachylaelapidae) was collected from Eleusine indica. Four species of Melicharidae were identified from 34 mites collected from within tree samples and 1,190 from vine or ground cover plants: Proctolaelaps lobatus was the most abundant species with 1,177 specimens collected from seven ground cover plants. One Phorytocarpais fimetorum (Parasitidae) was collected from inner leaves and four from twigs. Species of Ascidae, Blattisociidae, Melicharidae, Laelapidae and Pachylaelapidae were collected from 31 of the 82 vine or ground cover plants sampled, representing only a small fraction of the total number of Phytoseiidae collected from the same plants. Including the collection records of Martin Muma prior to 1975, a total of 69 species of Ascidae, Blattisociidae, Laelapidae, Macrochelidae, Melicharidae, Pachylaelapidae and Parasitidae have now been reported from citrus in Florid

Multi-Site Observational Study to Assess Biomarkers for Susceptibility or Resilience to Chronic Pain: The Acute to Chronic Pain Signatures (A2CPS) Study Protocol.

Chronic pain has become a global health problem contributing to years lived with disability and reduced quality of life. Advances in the clinical management of chronic pain have been limited due to incomplete understanding of the multiple risk factors and molecular mechanisms that contribute to the development of chronic pain. The Acute to Chronic Pain Signatures (A2CPS) Program aims to characterize the predictive nature of biomarkers (brain imaging, high-throughput molecular screening techniques, or "omics," quantitative sensory testing, patient-reported outcome assessments and functional assessments) to identify individuals who will develop chronic pain following surgical intervention. The A2CPS is a multisite observational study investigating biomarkers and collective biosignatures (a combination of several individual biomarkers) that predict susceptibility or resilience to the development of chronic pain following knee arthroplasty and thoracic surgery. This manuscript provides an overview of data collection methods and procedures designed to standardize data collection across multiple clinical sites and institutions. Pain-related biomarkers are evaluated before surgery and up to 3 months after surgery for use as predictors of patient reported outcomes 6 months after surgery. The dataset from this prospective observational study will be available for researchers internal and external to the A2CPS Consortium to advance understanding of the transition from acute to chronic postsurgical pain

Predicting chronic postsurgical pain: current evidence and a novel program to develop predictive biomarker signatures

AbstractChronic pain affects more than 50 million Americans. Treatments remain inadequate, in large part, because the pathophysiological mechanisms underlying the development of chronic pain remain poorly understood. Pain biomarkers could potentially identify and measure biological pathways and phenotypical expressions that are altered by pain, provide insight into biological treatment targets, and help identify at-risk patients who might benefit from early intervention. Biomarkers are used to diagnose, track, and treat other diseases, but no validated clinical biomarkers exist yet for chronic pain. To address this problem, the National Institutes of Health Common Fund launched the Acute to Chronic Pain Signatures (A2CPS) program to evaluate candidate biomarkers, develop them into biosignatures, and discover novel biomarkers for chronification of pain after surgery. This article discusses candidate biomarkers identified by A2CPS for evaluation, including genomic, proteomic, metabolomic, lipidomic, neuroimaging, psychophysical, psychological, and behavioral measures. Acute to Chronic Pain Signatures will provide the most comprehensive investigation of biomarkers for the transition to chronic postsurgical pain undertaken to date. Data and analytic resources generatedby A2CPS will be shared with the scientific community in hopes that other investigators will extract valuable insights beyond A2CPS's initial findings. This article will review the identified biomarkers and rationale for including them, the current state of the science on biomarkers of the transition from acute to chronic pain, gaps in the literature, and how A2CPS will address these gaps